Updates

Brave Bison

October 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Brave Bison’s interims show gross revenue up 15% to £16.9m and net revenue increased 23% to £10m, both driven primarily by the contribution from SocialChain. Pretax profit increased 16% to £1.5m. One-off restructuring and acquisition costs led to a statutory loss of £0.2m. The SocialChain acquisition has now bedded in with back-office functions combined and overall SocialChain headcount reducing by 28% since the deal completed. The combined business has won a number of new clients including The Army and Holland & Barrett. Elsewhere within the Brave Bison Commerce and Performance divisions, it also continued to win contracts with Markel Group and Asus. Broker Cavendish forecasts £3.1m pretax profit/eps 0.23p for the ful ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Gaming Realms

THG

Brave Bison (October 2024)

Brave Bison (September 2024)

Brave Bison (July 2024)

Brave Bison (June 2023)

Brave Bison - High growth and exciting (February 2023)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X